drugset / Trial / NCT03095612
Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)
Phase 1/2
Terminated
41 enrolled
University of Texas Southwestern Medical Center
Karyopharm Therapeutics Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is being done to evaluate the safety of the investigational study drug, selinexor when given with docetaxel to patients who have been previously treated for advanced KRAS mutant lung cancer.
Timeline
- Start
- 2018-03-22
- Primary completion
- 2022-11-08
- Completion
- 2023-03-03
Outcome
Outcome not reported
Stopped (Business): “Funding Sponsor no longer supporting study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |